Page last updated: 2024-12-06

azoxymethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Azoxymethane (AOM) is a potent colon carcinogen that has been widely used in experimental studies to investigate the mechanisms of colorectal cancer development. AOM is typically synthesized through a multi-step process involving the reaction of N-methyl-N-nitrosourea (MNU) with sodium azide. AOM acts as a direct-acting alkylating agent, inducing DNA damage and mutations in colon epithelial cells. AOM is frequently employed in animal models to study the carcinogenic process, as it reliably induces colonic tumors with a high degree of reproducibility. The induction of tumors by AOM is influenced by factors such as dose, route of administration, and genetic susceptibility of the animal. AOM research has contributed significantly to our understanding of the molecular pathways involved in colon cancer, including the role of inflammation, oxidative stress, and aberrant Wnt signaling. The use of AOM in research provides valuable insights into the development of novel therapeutic strategies for colon cancer prevention and treatment.'

Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID33184
MeSH IDM0002089

Synonyms (31)

Synonym
25843-45-2
nsc-171779
nsc171779
azoxymethane
diazene, dimethyl-, 1-oxide
[(z)-methyl-nno-azoxy]methane
AOM ,
ccris 67
methane, azoxy-
nsc 171779
azoxymethane, practical grade, 13.4 m, >=90% (gc)
methyl-methylimino-oxidoazanium
AKOS006272999
54168-20-6
unii-mo0n1j0sen
mo0n1j0sen ,
FT-0622536
GS-2507
(e)-dimethyldiazen-1-ium-1-olate
DTXSID3020124
AKOS028108420
azoxymethane, 13.4 m, >=98%
J-016148
CS-0040219
HY-111375
(e)-1,2-dimethyldiazene oxide
Q794084
A17109
BCP30116
(methyl-onn-azoxy)methane
DTXSID70860350

Research Excerpts

Overview

Azoxymethane (AOM) is an alkylating agent that generates mutagenic and carcinogenic O(6)-methylguanine (O(6)meG) adducts in DNA. The cytotoxicity of AOM mediated by oxidative stress.

ExcerptReferenceRelevance
"Azoxymethane (AOM) is a potent carcinogenic agent commonly used to induce colon cancer in rats and mice, with the cytotoxicity of AOM mediated by oxidative stress."( Protective role of a melon superoxide dismutase combined with gliadin (GliSODin) on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis.
Baba-Ahmed, F; Guedri, K; Ouali, K; Trea, F,
)
1.77
"Azoxymethane (AOM) is a widely used carcinogen to study chemical-induced colorectal carcinogenesis and is an agent for studying fulminant hepatic failure. "( Host genetics and gut microbiota cooperatively contribute to azoxymethane-induced acute toxicity in Collaborative Cross mice.
Celniker, SE; Chang, H; He, L; Lee, SY; Mao, JH; Snijders, AM; Threadgill, DW; Xia, Y; Yuan, Y; Zhang, Y; Zhong, C; Zhou, F, 2021
)
2.31
"Azoxymethane (AOM) is a potent cancer inducer widely used in rats for colon cancer."( Chemoprotective Effects of Geraniin against Azoxymethane Induced Colorectal Cancer by Reduction of Inflammatory Reaction.
Lei, J; Wei, Y; Zhang, H; Zhou, R, 2021
)
1.6
"Azoxymethane (AOM) is an alkylating agent that generates mutagenic and carcinogenic O(6)-methylguanine (O(6)meG) adducts in DNA. "( Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis.
Head, RJ; Hu, Y; Kim, SW; Le Leu, RK; Lockett, TJ; Margison, GP; Nyskohus, LS; Watson, AJ; Young, GP, 2013
)
2.15
"Azoxymethane (AOM) is a potent carcinogenic agent commonly used to induce colon cancer in rats; the cytotoxicity of AOM is considered to mediate oxidative stress. "( Amelioration of azoxymethane induced-carcinogenesis by reducing oxidative stress in rat colon by natural extracts.
Al Riyami, M; Al-Alawi, A; Al-Issaei, HK; Al-Kindi, MA; Al-Rawahi, AS; Farooq, SA; Rahman, MS; Waly, MI, 2014
)
2.19
"Azoxymethane (AOM) is a potent genotoxic carcinogen which specifically induces colon cancer. "( Canola oil influence on azoxymethane-induced colon carcinogenesis, hypertriglyceridemia and hyperglycemia in Kunming mice.
Cichello, SA; Duan, JL; He, XQ; Zhou, J, 2014
)
2.15
"Azoxymethane (AOM) is a potent carcinogen used for induction of colon tumors in rats and mice. "( Induction of duodenal mucosal tumors of intestinal epithelial cell origin showing frequent nuclear β-catenin accumulation similar to the concurrently induced colorectal tumors in rats after treatment with azoxymethane.
Kangawa, Y; Kikuchihara, Y; Kimura, M; Mizukami, S; Onda, N; Shibutani, M; Yoshida, T,
)
1.76
"Azoxymethane (AOM) is a common model for colon cancer."( The signal pathways in azoxymethane-induced colon cancer and preventive implications.
Chen, J; Huang, XF, 2009
)
1.38
"Azoxymethane is a potential carcinogen to induce the colon cancer in Swiss albino mice."( Immunomodulatory effects of Withania somnifera on azoxymethane induced experimental colon cancer in mice.
Dinda, AK; Muralikrishnan, G; Shakeel, F, 2010
)
1.34
"Azoxymethane (AOM) is a methylating agent capable of inducing mutations in DNA by forming adducts with DNA bases. "( Is the tissue persistence of O(6)-methyl-2'-deoxyguanosine an indicator of tumour formation in the gastrointestinal tract?
Clarke, JM; Cosgrove, LJ; Gerber, JP; Head, RJ; Lockett, TJ; Tan, SL; Williams, DB, 2011
)
1.81
"Azoxymethane (AOM) is a colon carcinogen that is used to study the pathogenesis of sporadic colorectal cancer. "( Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors.
Girnun, G; Guda, K; Lillo, NA; Nambiar, PR; Rosenberg, DW; Whiteley, HE, 2003
)
2.07
"Azoxymethane (AOM) is a potent carcinogen that induces colorectal cancer and adenomas in rats. "( Noninvasive monitoring of colonic carcinogenesis: feasibility of [(18)F]FDG-PET in the azoxymethane model.
Drenth, JP; Laverman, P; Nagengast, FM; Oyen, WJ; van Kouwen, MC; van Krieken, JH, 2006
)
2
"Azoxymethane (AOM) is a potent DNA-damaging agent and carcinogen that induces intestinal and colonic tumors in rodents. "( Azoxymethane protects intestinal stem cells and reduces crypt epithelial mitosis through a COX-1-dependent mechanism.
Anant, S; Dieckgraefe, B; George, RJ; Houchen, CW; May, R; Riehl, TE; Sturmoski, MA, 2006
)
3.22
"Azoxymethane (AOM) is an organotropic colon carcinogen that is commonly used to induce colon tumors in rodents. "( Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility.
Delker, DA; Papanikolaou, A; Rosenberg, DW; Wang, QS, 1998
)
3.19

Effects

ExcerptReferenceRelevance
"The azoxymethane (AOM) model has been widely used to investigate the pathology and genetics of colorectal cancer in rodents. "( Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet.
Amann, V; Bissahoyo, A; Godfrey, VL; Hanlon, K; Hicks, D; Pearsall, RS; Threadgill, DW, 2005
)
2.33

Actions

ExcerptReferenceRelevance
"The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane."( Study of superoxide dismutase's expression in the colon produced by azoxymethane and inositol hexaphosfate's paper, in mice.
Amaral, EG; Fagundes, DJ; Inouye, CM; Marks, G, 2006
)
1.13

Treatment

Azoxymethane/DSS-treated Nrf2 knockout mice had increased incidence, multiplicity, and size of all colorectal tumors, including adenomas. The proportion of tumors that were adenocarcinoma was much higher in knockout (80%) versus WT (29%) mice.

ExcerptReferenceRelevance
"Azoxymethane (AOM)-treated, Apc"( Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice.
Kang, X; Kwong, TNY; Lam, TYT; Lin, Y; Liu, C; Ng, SK; Ni, Y; Sung, JJY; Wei, H; Wong, SH; Wu, WKK; Yu, J; Zhou, Y, 2023
)
2.35
"Azoxymethane-treated mice developed FHF and hepatic encephalopathy, associated with higher autotaxin (ATX) activities in serum than controls."( Lysophosphatidic acid receptor, LPA
Hamano, F; Kihara, Y; Masago, K; Nakagawa, S; Niwa, M; Shimizu, T; Yanagida, K, 2018
)
1.2
"Azoxymethane-treated mice were euthanized at time points representing absence of minor and significant stages of neurological decline."( Direct Comparison of the Thioacetamide and Azoxymethane Models of Type A Hepatic Encephalopathy in Mice.
DeMorrow, S; Frampton, G; Grant, S; Jaeger, V; Kain, J; McMillin, M; Petrescu, AD; Williams, E, 2018
)
1.46
"Azoxymethane/DSS-treated Nrf2 knockout mice had increased incidence, multiplicity, and size of all colorectal tumors, including adenomas, versus treated wild-type (WT) mice, and the proportion of tumors that were adenocarcinoma was much higher in knockout (80%) versus WT (29%) mice."( Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer.
Chan, JY; Cheung, WK; Hao, X; Huang, MT; Khor, TO; Kong, AN; Liu, Y; Prawan, A; Reddy, BS; Yang, CS; Yu, S, 2008
)
1.07
"Azoxymethane-treated rats were randomized to AIN-76A diet alone or supplemented with 5% PEG-8000."( Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling.
Backman, V; Bissonnette, M; Goldberg, M; Hart, J; Kim, YL; Koetsier, JL; Kunte, DP; Liu, Y; Roy, HK; Wali, RK, 2006
)
1.06
"In azoxymethane-treated M(3)R(-/-) mice, cell proliferation (BrdUrd staining) was reduced 43% compared with azoxymethane-treated WT mice (P < 0.05)."( Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia.
Cheng, K; Drachenberg, C; Khurana, S; Raufman, JP; Samimi, R; Shah, N; Shant, J; Wess, J; Xie, G, 2008
)
0.86
"When treated with azoxymethane and dextran sodium sulphate (AOM/DSS) as a model of IBD, Gsto1-/- mice were highly sensitive to colitis and showed a significant increase in the size and number of colon tumours compared with wild-type (WT) mice."( Glutathione transferase Omega 1 confers protection against azoxymethane-induced colorectal tumour formation.
Board, PG; Casarotto, MG; Dahlstrom, JE; Fernando, N; Hughes, MM; O'Neill, LAJ; Rooke, M; Takahashi, S; Tummala, P, 2021
)
1.19
"Treatment with azoxymethane (AOM; 200 μg/mouse injected once a week for 3 times) resulted in markedly increased colon aberrant crypt foci (ACF) development (≈70 ACF/mouse) in KK-A(y) mice compared with lean C57BL/6J mice (≈9 ACF/mouse)."( High susceptibility to azoxymethane-induced colorectal carcinogenesis in obese KK-Ay mice.
Imai, T; Masuda, S; Mutoh, M; Nakano, K; Sugimura, T; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K, 2011
)
1.02
"Rats treated with azoxymethane displayed lower levels of I-compounds in colon DNA compared with control groups (0 hour)."( Tissue-specific attenuation of endogenous DNA I-compounds in rats by carcinogen azoxymethane: possible role of dietary fish oil in colon cancer prevention.
Chapkin, RS; Donnelly, KC; Lupton, JR; Popovic, N; Turner, ND; Zhou, GD, 2005
)
0.88
"Treatment with azoxymethane did not significantly alter fecal bile acid composition in the rats."( Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps.
Alberts, D; Batta, AK; Brasitus, TA; Earnest, DL; Holubec, H; Salen, G, 1998
)
0.64
"Rats treated with azoxymethane and intrarectal DCA developed significantly more colorectal cancers than rats receiving azoxymethane and intrarectal saline (median 11.5, range 8-17 vs."( Effect of deoxycholic acid on the tumour incidence, distribution, and receptor status of colorectal cancer in the rat model.
Goeting, N; Summerton, J; Taylor, I; Trotter, GA, 1985
)
0.59

Toxicity

ExcerptReferenceRelevance
" GTE was not toxic and no harmful effect was found during its clinical use."( Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis.
Iwata, Y; Kikuoka, N; Kitao, Y; Matsumoto, H; Nakatani, H; Oya, K; Takahashi, T; Yamane, T, 1996
)
0.29
"We have consistently shown that several synthetic Organoselenium compounds are superior cancer chemopreventive agents and less toxic than selenite or certain naturally occurring selenoamino acids."( Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity.
Cooma, I; El-Bayoumy, K; Rao, CV; Reddy, BS; Rodriguez, JG; Simi, B; Wang, CQ, 2001
)
0.31
" In the present study, the effects of mild hypothermia in relation to liver pathology, hepatic and cerebral glutathione, plasma ammonia concentrations, progression of encephalopathy, cerebral edema, and plasma proinflammatory cytokines were assessed in mice with ALF resulting from azoxymethane (AOM) hepatotoxicity, a well characterized model of toxic liver injury."( Antioxidant and anti-inflammatory effects of mild hypothermia in the attenuation of liver injury due to azoxymethane toxicity in the mouse.
Bémeur, C; Butterworth, RF; Desjardins, P, 2010
)
0.75
" There were no adverse effects observed in the probiotic control group."( Probiotic Pediococcus pentosaceus strain GS4 alleviates azoxymethane-induced toxicity in mice.
Bishayee, K; Dubey, V; Ghosh, AR; Khuda-Bukhsh, AR, 2015
)
0.66
" KH was not toxic to the animals since the level of blood profile parameters, liver enzymes, and kidney functions was in normal range."( Chemopreventive Properties and Toxicity of Kelulut Honey in Sprague Dawley Rats Induced with Azoxymethane.
Esa, N; Gopalsamy, B; Mohd Ali, R; Muhamad Zali, MF; Ong, YS; Saiful Yazan, L; Sapuan, S; Syed Alwi, SS; Tor, YS; Voon, FL; Zainal, NA, 2016
)
0.65

Compound-Compound Interactions

ExcerptReferenceRelevance
" Experiments were designed to assess the potential chemopreventive properties of highly selective iNOS inhibitors, administered individually and in combination with a selective COX-2 inhibitor, on the development of AOM-induced colonic aberrant crypt foci (ACF)."( Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Connor, JR; Indranie, C; Manning, PT; Rao, CV; Reddy, BS; Simi, B, 2002
)
0.31
" The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats."( Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV, 2009
)
0.93

Bioavailability

ExcerptReferenceRelevance
" The form in which Se is presented in the diet may influence significantly its bioavailability and/or anticancer potential at given concentrations within a safe range."( Selenised casein protects against AOM-induced colon tumors in Sprague Dawley rats.
Lesno, S; McIntosh, GH; Royle, PJ; Scherer, BL, 2006
)
0.33
"The chemical form and bioavailability of dietary selenium may influence its protectiveness against colorectal cancer."( Suppression of colorectal oncogenesis by selenium-enriched milk proteins: apoptosis and K-ras mutations.
Hu, Y; Le Leu, RK; McIntosh, GH; Woodman, R; Young, GP, 2008
)
0.35
"Curcumin is a potential natural anticancer drug with limited bioavailability due to the lack of solubility in aqueous solvents."( Chemoprevention of azoxymethane-initiated colon cancer in rat by using a novel polymeric nanocarrier--curcumin.
Alizadeh, AM; Azizian, S; Khaniki, M; Mohaghgheghi, MA; Najafi, F; Sadeghizadeh, M, 2012
)
0.71
" Previously, we showed that the selective iNOS inhibitor S,S'-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues."( Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats.
Amin, S; Choi, CI; Desai, D; Janakiram, NB; Mohammed, A; Rao, CV; Ravillah, D; Zhang, Y, 2013
)
0.58

Dosage Studied

Azoxymethane-induced adenocarcinoma rats were dosed with indomethacin and copper-indomethACin for 28 days. The dose-response relationship in male F344 rats was determined for the ability of aspirin to prevent colon cancer and aberrant crypt foci (ACF)

ExcerptRelevanceReference
" A dose-response relationship was observed in both mouse strains between the level of dietary cholesterol or oxidized cholesterol and formation of preneoplastic aberrant crypt foci."( Effect of dietary oxidized cholesterol on azoxymethane-induced colonic preneoplasia in mice.
Kendall, CW; Koo, M; Rao, AV; Sokoloff, E, 1992
)
0.55
") and controls dosed with saline."( The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis.
Cooke, T; Reeves, JR; Richards, RC, 1991
)
0.28
" The purpose of this study was to determine whether InsP6 (i) shows a dose-response inhibition of LIC, and (ii) retains its anti-neoplastic effect at physiological pH."( Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats.
Shamsuddin, AM; Ullah, A, 1990
)
0.28
" Previous studies in animal models restricted the calorie intake severely, and none of these studies have investigated a dose-response effect of different levels of calorie restriction on colon carcinogenesis."( Effect of different levels of calorie restriction on azoxymethane-induced colon carcinogenesis in male F344 rats.
Kumar, SP; Reddy, BS; Roy, SJ; Tokumo, K, 1990
)
0.53
" These rats were fed diet containing 100 or 200 ppm KYN-54 for 5 weeks, starting 1 week before the first dosing of AOM."( Suppression of azoxymethane-induced colonic aberrant crypt foci by dietary exposure to a novel synthesized retinoidal butenolide, 5-hydroxy-4-(2-phenyl-(E)ethenyl)-2(5H)-furanone, in rats.
Hara, A; Hirose, Y; Kawamori, T; Mori, H; Satoh, K; Tamai, Y; Tanaka, T; Torihara, M; Yamahara, J, 1995
)
0.64
" These rats were fed the diet containing 200 ppm of each test chemical for 5 weeks, starting 1 week before the first dosing of AOM."( Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats.
Hara, A; Kawamori, T; Mori, H; Tanaka, T; Yamahara, J, 1995
)
0.5
" These rats were fed diet containing 1000 or 2000 ppm PCA for 5 weeks, starting one week before the first dosing of AOM."( Suppression of azoxymethane-induced rat colon aberrant crypt foci by dietary protocatechuic acid.
Kawamori, T; Kojima, T; Mori, H; Ohnishi, M; Suzui, M; Tanaka, T, 1994
)
0.64
" Fifty-six three-week-old male Wistar rats were randomly assigned to four groups and dosed subcutaneously with AOM (15 mg/kg body wt) once a week for 2 weeks."( Effect of potato starch, cornstarch and sucrose on aberrant crypt foci in rats exposed to azoxymethane.
Kristiansen, E; Meyer, O; Thorup, I,
)
0.35
"5% d-limonene in the drinking water, starting 1 week before the first dosing with AOM."( Inhibitory effects of d-limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats.
Hirose, Y; Kawamori, T; Mori, H; Ohnishi, M; Tanaka, T, 1996
)
0.51
" The rats were fed a basal diet containing either 12% olive oil, 12% safflower oil, 12% perilla oil, 6% perilla oil plus 6% olive oil, or 3% perilla oil plus 9% olive oil for 5 weeks, starting 1 week before the first dosing of AOM."( Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats.
Kawamori, T; Komaki, C; Mori, H; Moriwaki, H; Muto, Y; Okuno, M; Onogi, N; Tanaka, T, 1996
)
0.57
" They also received the diet containing 200 ppm test compound for 5 weeks, starting one week before the first dosing of AOM."( Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon.
Hara, A; Hirose, Y; Maeda, M; Makita, H; Mori, H; Satoh, K; Tanaka, T; Toriyama, HB; Tsuda, H; Yang, M, 1996
)
0.51
" After four weeks only the mice dosed with IQ and PhIP had aberrant crypt foci."( The ability of two cooked food mutagens to induce aberrant crypt foci in mice.
Kristiansen, E; Meyer, O; Thorup, I, 1997
)
0.3
" They were fed the diets containing 100 or 200 ppm ACA for 5 weeks, starting 1 week before the first dosing of AOM."( A xanthine oxidase inhibitor 1'-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats.
Hara, A; Kawabata, K; Kawamori, T; Koshimizu, K; Makita, H; Mori, H; Murakami, A; Ohigashi, H; Satoh, K; Tanaka, T, 1997
)
0.53
" Sulfone-treated rats also showed a dose-response relationship for inhibiting all tumor parameters."( Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Ahnen, DJ; Alberts, DS; Bogert, C; Brendel, K; Burt, RW; Ellsworth, L; Finn, T; Gross, PH; Guillen, JM; Hixson, LJ; Li, H; Pamukcu, R; Paranka, NS; Piazza, GA; Ritchie, J; Sperl, G, 1997
)
0.6
" They were fed diet containing 100 or 500 ppm ACA for 4 weeks, starting one week before the first dosing of AOM (the initiation feeding)."( Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate.
Hara, A; Kakumoto, M; Kawabata, K; Koshimizu, K; Makita, H; Matsunaga, K; Mori, H; Murakami, A; Ohigashi, H; Satoh, K; Tanaka, T, 1997
)
0.63
" After determining the maximally tolerated dosage of the tea products, their effect in a colon cancer model was investigated."( Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer.
Aliaga, C; Balentine, DA; Boone, CW; Kelloff, GJ; Pittman, B; Reinhardt, J; Rivenson, A; Steele, VE; Weisburger, JH; Zang, E, 1998
)
0.53
" Another group received the AOM dosage at 6 and 7 weeks and were placed on the tea solutions 2 days after the last AOM dosage, at 51 days of age, and held for the 50-week period."( Effect of black tea on azoxymethane-induced colon cancer.
Aliaga, C; Braley, J; Pittman, B; Reinhardt, J; Rivenson, A; Weisburger, JH; Zang, E, 1998
)
0.61
" Unlike the demonstrated prevention of colon cancer by the other two retinoids, both dosing schedules of 2-CPR resulted in an approximate doubling of the yield of colon tumors."( Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci.
Kelloff, GJ; Kramer, PM; Lubet, RA; Pereira, MA; Steele, VE; Zheng, Y, 1999
)
0.3
"The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels."( Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999
)
0.74
" They also received the experimental diets containing one of test compounds (500 ppm) for 5 weeks, starting one week before the first dosing of AOM."( Inhibition of azoxymethane-induced aberrant crypt foci in rats by natural compounds, caffeine, quercetin and morin.
Honjo, S; Kawabata, K; Kohno, H; Matsunaga, K; Murakami, M; Shimada, R; Shimizu, M; Tanaka, T; Yamada, Y,
)
0.49
" In the present study, we tested the effect of PEG administered during either initiation or postinitiation, the dose-response effect of PEG, the regressive effect of PEG on established ACF, and the preventive effect of PEG on colon cancers in rats."( Polyethylene-glycol suppresses colon cancer and causes dose-dependent regression of azoxymethane-induced aberrant crypt foci in rats.
Corpet, DE; Parnaud, G; Peiffer, G; Taché, S, 1999
)
0.53
" This study examined the dose-response effect of celecoxib when administered during the initiation and postinitiation stages."( Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Hirose, Y; Kelloff, G; Lubet, R; Paulson, S; Rao, CV; Reddy, BS; Seibert, K; Steele, V, 2000
)
0.31
" Dosing of 100 mg/kg significantly elevated GST activity in liver (P<0."( Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats.
Hara, A; Kawabata, K; Matsunaga, K; Mori, H; Shimizu, M; Tanaka, T; Yamada, Y; Yamamoto, T, 2000
)
0.58
" They also received MJ, MJ2, or MJ5 as a drinking water at night for 36 weeks, starting 1 week after the last dosing of AOM."( Suppression of azoxymethane-induced colon carcinogenesis in male F344 rats by mandarin juices rich in beta-cryptoxanthin and hesperidin.
Azuma, Y; Kagami, S; Kohno, H; Murakami, M; Ogawa, H; Shimada, R; Sumida, T; Tanaka, T, 2000
)
0.66
" SFN and PEITC and their NAC conjugates were administered by gavage either three times weekly for 8 weeks (5 and 20 micromol, respectively) after AOM dosing (post-initiation stage) or once daily for 3 days (20 and 50 micromol, respectively) before AOM treatment (initiation stage)."( Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate.
Chung, FL; Conaway, CC; Rao, CV; Reddy, BS, 2000
)
0.31
" Groups 2 and 3 also received experimental diet containing celecoxib (500 and 1500 ppm, respectively) for 8 weeks, starting a week before the first dosing of AOM."( Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.
Hara, A; Hirose, Y; Katayama, M; Kuno, T; Mori, H; Qiao, Z; Shimizu, M; Yamada, Y; Yoshimi, N, 2001
)
0.31
"05% nobiletin for 5 weeks, starting one week before the first dosing of AOM."( Dietary administration of citrus nobiletin inhibits azoxymethane-induced colonic aberrant crypt foci in rats.
Kohno, H; Koshimizu, K; Murakami, A; Nishino, H; Ohigashi, H; Tanaka, T; Tokuda, H; Tsukio, Y; Yano, M; Yoshitani, S, 2001
)
0.56
"05% zerumbone for 5 weeks, starting one week before the first dosing of AOM."( Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet.
Kohno, H; Koshimizu, K; Mori, H; Murakami, A; Ohigashi, H; Safitri, R; Shimizu, M; Takahashi, D; Tanaka, T; Tsukio, Y; Yamamoto, K; Yoshitani, S, 2001
)
0.64
"1% or 1% CLN for 5 weeks, starting one week before the first dosing of AOM."( Dietary conjugated linolenic acid inhibits azoxymethane-induced colonic aberrant crypt foci in rats.
Hosokawa, M; Kohno, H; Miyashita, K; Noguchi, R; Suzuki, R; Tanaka, T, 2002
)
0.58
" They were fed the experimental diets mixed with columbin (4, 20, and 100 ppm) for 4 weeks, starting 1 week before the first dosing of AOM and thereafter maintained on the basal diet without columbin."( A bitter diterpenoid furanolactone columbin from Calumbae Radix inhibits azoxymethane-induced rat colon carcinogenesis.
Kohno, H; Maeda, M; Mori, H; Sugie, S; Tanaka, T; Tanino, M; Tsukio, Y; Ueda, N; Wada, K, 2002
)
0.55
" Colorectal carcinogenesis developed with the increasing duration of diarrhea induced by 3% dextran sulphate sodium in mice pretreated by a single injection of a small dosage of azoxymethane during the comparatively short period of this experimental colitis system."( The more an ulcerative colitis is repeated, the more the risk of colorectal carcinogenesis is increased in mice.
Kudo, H; Mitamura, T; Okayasu, I; Sakamoto, S; Sassa, S; Suzuiki, S,
)
0.32
"2% EK for 4 weeks, starting 1 week before the first dosing of AOM."( Extract of vinegar "Kurosu" from unpolished rice inhibits the development of colonic aberrant crypt foci induced by azoxymethane.
Hayashi, R; Kohno, H; Nanda, K; Nishikawa, Y; Ohigashi, H; Shimoji, Y; Sugie, S; Tamura, Y; Tanaka, T; Uenakai, K, 2003
)
0.53
"1% or 1% BMO for 32 weeks, starting 1 week before the first dosing of AOM."( Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition.
Hosokawa, M; Kohno, H; Miyashita, K; Suzuki, R; Tanaka, T; Yasui, Y, 2004
)
0.55
" They also received the experimental diets containing EGb (50 or 500 ppm) and bilobalide (15 or 150 ppm) for 4 weeks, starting 1 week before the first dosing of AOM."( Preventive effects of extract of leaves of ginkgo (Ginkgo biloba) and its component bilobalide on azoxymethane-induced colonic aberrant crypt foci in rats.
Kohno, H; Sasaki, K; Sugie, S; Suzuki, R; Tanaka, T; Wada, K; Yoshimura, T, 2004
)
0.54
"1% EK for 35 wk, starting 1 wk after the last dosing of AOM."( Extract of Kurosu, a vinegar from unpolished rice, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats.
Kohno, H; Nanda, K; Nishikawa, Y; Ohigashi, H; Shimoji, Y; Tanaka, T; Uenakai, K, 2004
)
0.57
" Its administration at higher dosage also significantly enhanced the development of pleural metastasis."( Induction by lysophosphatidic acid of peritoneal and pleural metastases of intestinal cancers induced by azoxymethane in Wistar rats.
Baba, M; Higashino, K; Iishi, H; Ishiguro, S; Ishihara, R; Mukai, M; Tatsuta, M; Uedo, N, 2005
)
0.54
"05% nobiletin for 34 weeks, starting one week after the last dosing of AOM."( Citrus nobiletin inhibits azoxymethane-induced large bowel carcinogenesis in rats.
Kohno, H; Koshimizu, K; Murakami, A; Nishino, H; Ohigashi, H; Suzuki, R; Tanaka, T; Tokuda, H; Yano, M, 2004
)
0.62
" Therefore, male DBA/2J mice were intraperitonially injected AOM (10 mg/kg body weight), and then 2% degraded lambda-carrageenan in drinking water for one or two weeks, starting one week after dosing of AOM."( Lack of enhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated crypts in male DBA/2J mice initiated with azoxymethane.
Hara, A; Hata, K; Hirose, Y; Kohno, H; Kuno, T; Mori, H; Qiang, SH; Suzuki, R; Tanaka, T, 2006
)
0.53
" In order to establish an optimal dosing regime for detecting experiment-dependent differences in tumorigenesis, we performed a dose curve analysis using AKR/J, SWR/J, and A/J mouse strains previously reported to vary widely in susceptibility to AOM."( Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet.
Amann, V; Bissahoyo, A; Godfrey, VL; Hanlon, K; Hicks, D; Pearsall, RS; Threadgill, DW, 2005
)
1.77
" Male F344 rats were injected subcutaneously with 15 mg/kg body weight of AOM in the back twice at 7-day intervals from 5 weeks of age, and fed a diet containing 600 or 1200 ppm mofezolac for 32 weeks, starting 1 day before the first dosing of AOM."( Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Kitamura, T; Matsuura, M; Mutoh, M; Niho, N; Sato, H; Sugimura, T; Takahashi, M; Wakabayashi, K, 2006
)
0.69
"1% or 1% CPO for 4 weeks, starting one week before the first dosing of AOM."( Catalpa seed oil rich in 9t,11t,13c-conjugated linolenic acid suppresses the development of colonic aberrant crypt foci induced by azoxymethane in rats.
Hosokawa, M; Kohno, H; Miyamoto, S; Miyashita, K; Suzuki, R; Tanaka, T; Yasui, Y, 2006
)
0.54
"1%, or 1% 9t,11t-CLA for 4 wk starting 1 wk before the first dosing of AOM."( 9trans,11trans conjugated linoleic acid inhibits the development of azoxymethane-induced colonic aberrant crypt foci in rats.
Beppu, F; Hosokawa, M; Kohno, H; Miyamoto, S; Miyashita, K; Suzuki, R; Tanaka, T; Yasui, Y, 2007
)
0.58
" According to the consuming assigned diets, all animals received AOM at a dosage of 15 mg/kg once a week for two consecutive weeks."( Effects of resistant starch on colonic preneoplastic aberrant crypt foci in rats.
Liu, R; Xu, G, 2008
)
0.35
" Male Wistar Hannover (GALAS) rats were administered two weekly subcutaneous injections of AOM (20 mg/kg bw) and fed with diets mixed with AEP (100, 500 and 1,000 ppm) or EEP (500 and 1,000 ppm) for 4 weeks, starting one week before the first dosing of AOM."( Aqueous and ethanolic extract fractions from the Brazilian propolis suppress azoxymethane-induced aberrant crypt foci in rats.
Kim, M; Kohno, H; Miyamoto, S; Sugie, S; Tanaka, T; Yasui, Y, 2008
)
0.57
"Azoxymethane-induced adenocarcinoma rats were dosed with indomethacin and copper-indomethacin for 28 days and aberrant crypt foci were evaluated."( Inhibition of experimental colorectal cancer and reduction in renal and gastrointestinal toxicities by copper-indomethacin in rats.
Bonin, AM; Davies, NM; Dillon, CT; Fukuda, C; Hambley, TW; Lay, PA; Teng, XW; Yáñez, JA, 2010
)
1.8
"0 mg/kg for 28 days, whereas copper-indomethacin at equimolar doses of indomethacin affected urine electrolytes after acute dosing but not after chronic dosing for 28 days."( Inhibition of experimental colorectal cancer and reduction in renal and gastrointestinal toxicities by copper-indomethacin in rats.
Bonin, AM; Davies, NM; Dillon, CT; Fukuda, C; Hambley, TW; Lay, PA; Teng, XW; Yáñez, JA, 2010
)
0.36
" A 4-day dosing schedule in vivo generated a similar response in colon tumors; growth arrest without significantly increased apoptosis."( Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Belinsky, GS; Giardina, C; Rigatti, MJ; Rosenberg, DW; Verma, R, 2012
)
0.38
" Omeprazole produced significant dose-response effects on inhibition of multi-crypt foci (≥4)."( Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats.
Li, Q; Patlolla, JM; Rao, CV; Steele, VE; Zhang, Y, 2012
)
0.6
" Animals received AOM at a dosage of 15 mg/kg body weight intraperitoneally once a week for 3 weeks."( Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis.
Dharmalingam, P; Ganapasam, S; Pandurangan, AK; Sadagopan, SK, 2014
)
0.65
" A sub-chronic and acute toxicity LD50 test of Rh2E2 showed no harmful reactions at the maximum oral dosage of 5000 mg/kg body weight in mice."( Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.
Bai, LP; Chan, KM; Chan, RW; Dong, H; Guo, J; Guo, Y; Hsiao, WW; Jiang, ZH; Kam, RK; Kong, AN; Law, BY; Leung, EL; Liang, X; Liu, L; Wang, J; Wang, R; Wong, VK; Yen, FG; Yu, Z; Zhang, W; Zhou, H, 2016
)
0.43
" A second dose-response experiment was performed using diets supplemented with the saturated-fatty-acid (SFA)-rich coconut oil."( High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer.
Cranford, TL; Davis, JM; Enos, RT; McClellan, JL; Murphy, EA; Nagarkatti, M; Nagarkatti, PS; Velázquez, KT, 2016
)
0.68
" In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer."( Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.
Barton, JK; Chandra, S; Gerner, EW; Nymeyer, AC; Rice, PF, 2017
)
0.88
" Animals that consumed the hypercaloric diet had a higher concentration of cholesterol and a higher atherogenic index, which were significantly reduced with the administration of chickpea protein hydrolysates with a dose-response effect (10, 20, or 30 mg/kg), whereas no effect was observed in animals that consumed the normal diet."( Protective Effect of Chickpea Protein Hydrolysates on Colon Carcinogenesis Associated With a Hypercaloric Diet.
Álvarez-González, I; Baltiérrez-Hoyos, R; Dávila-Ortiz, G; Garduño-Siciliano, L; Jiménez Martínez, C; León-Espinosa, EB; Madrigal-Bujaidar, E; Sánchez-Chino, XM; Vásquez-Garzón, VR, 2019
)
0.51
" Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen."( Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.
Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019
)
0.76
" An initial dosing study performed in healthy mice indicates that aspirin at a dose of 25 mg/kg/d has a similar pharmacodynamic effect as low-dose aspirin treatment in human subjects (100 mg/d)."( Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Hartung, NM; Kühl, AA; McDonald, FM; Ostermann, AI; Rohwer, N; Schebb, NH; Weylandt, KH; Zopf, D, 2020
)
0.56
" In particular, a high rate of cancer was observed at 10 and 20 weeks after administration in 12-week-old CD4-dnTGFβRII mice dosed at 15 mg/kg."( Establishment of a Novel Colitis-Associated Cancer Mouse Model Showing Flat Invasive Neoplasia.
Ando, Y; Aoi, M; Fukui, T; Horitani, S; Matsumoto, Y; Naganuma, M; Okazaki, K; Tanaka, H; Tomiyama, T; Tsuneyama, K; Uragami, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,693)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990135 (7.97)18.7374
1990's306 (18.07)18.2507
2000's446 (26.34)29.6817
2010's611 (36.09)24.3611
2020's195 (11.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.38 (24.57)
Research Supply Index7.48 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index51.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.06%)5.53%
Reviews22 (1.25%)6.00%
Case Studies1 (0.06%)4.05%
Observational3 (0.17%)0.25%
Other1,739 (98.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]